OAM
NBIX icon

Oppenheimer Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Oppenheimer Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.89M Sell
14,313
-99
-0.7% -$13.1K 0.02% 569
2025
Q4 		$2.04M Sell
14,412
-968
-6% -$140K 0.03% 497
2025
Q3 		$2.16M Sell
15,380
-815
-5% -$110K 0.02% 541
2025
Q2 		$2.04M Buy
16,195
+2,202
+16% +$253K 0.02% 547
2025
Q1 		$1.55M Buy
13,993
+49
+0.4% +$6.21K 0.02% 599
2024
Q4 		$1.9M Buy
13,944
+186
+1% +$23K 0.02% 549
2024
Q3 		$1.59M Sell
13,758
-1,388
-9% -$190K 0.02% 614
2024
Q2 		$2.09M Buy
15,146
+1,725
+13% +$237K 0.03% 511
2024
Q1 		$1.85M Sell
13,421
-2,056
-13% -$281K 0.03% 512
2023
Q4 		$2.04M Sell
15,477
-452
-3% -$52K 0.03% 510
2023
Q3 		$1.79M Buy
15,929
+1,736
+12% +$183K 0.03% 527
2023
Q2 		$1.34M Sell
14,193
-12,027
-46% -$1.18M 0.02% 612
2023
Q1 		$2.65M Sell
26,220
-196
-0.7% -$20.4K 0.04% 418
2022
Q4 		$3.16M Sell
26,416
-3,833
-13% -$449K 0.05% 365
2022
Q3 		$3.21M Sell
30,249
-3,444
-10% -$349K 0.06% 338
2022
Q2 		$3.29M Sell
33,693
-920
-3% -$84.9K 0.06% 347
2022
Q1 		$3.25M Buy
34,613
+8,179
+31% +$693K 0.05% 399
2021
Q4 		$2.25M Sell
26,434
-2,362
-8% -$217K 0.03% 520
2021
Q3 		$2.76M Buy
28,796
+354
+1% +$33.4K 0.04% 428
2021
Q2 		$2.77M Buy
28,442
+674
+2% +$64.6K 0.04% 442
2021
Q1 		$2.7M Buy
27,768
+2,532
+10% +$266K 0.04% 427
2020
Q4 		$2.42M Sell
25,236
-639
-2% -$61.7K 0.04% 423
2020
Q3 		$2.49M Buy
25,875
+16,149
+166% +$1.87M 0.05% 381
2020
Q2 		$1.19M Buy
9,726
+785
+9% +$86.7K 0.02% 547
2020
Q1 		$774K Buy
8,941
+1,383
+18% +$135K 0.02% 621
2019
Q4 		$812K Buy
7,558
+82
+1% +$8.59K 0.02% 683
2019
Q3 		$674K Buy
7,476
+204
+3% +$19.1K 0.02% 729
2019
Q2 		$614K Sell
7,272
-203
-3% -$16.7K 0.01% 763
2019
Q1 		$659K Buy
7,475
+700
+10% +$58.5K 0.01% 719
2018
Q4 		$484K Buy
+6,775
New +$649K 0.01% 777

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer Asset Management's NBIX Position: Q1 2026 in Review

Oppenheimer Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 0.69% in Q1 2026, selling an estimated $13.1K and leaving 14,313 shares worth $1.89M. The position accounts for 0.02% of the portfolio, ranked #569.

Oppenheimer Asset Management first reported a position in NBIX in Q4 2018 and has held it in 30 quarters since. The position peaked at $3.29M in Q2 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Oppenheimer Asset Management held 14,313 shares of Neurocrine Biosciences worth $1.89M as of Q1 2026.
  • Oppenheimer Asset Management sold 99 Neurocrine Biosciences shares in Q1 2026, an estimated $13.1K.
  • Neurocrine Biosciences made up 0.02% of Oppenheimer Asset Management's portfolio in Q1 2026, its #569 holding.
  • Oppenheimer Asset Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 30 quarters since.
  • Oppenheimer Asset Management's Neurocrine Biosciences position peaked at $3.29M in Q2 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.